← All trials
NCT02170246
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2014
- Primary completion
- Feb 1, 2018
- Completion date
- Feb 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 21
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Yale UniversityLead sponsor
- Yale UniversityOverall official - principal investigator
- Thai Red Cross AIDS Research Centre, Bangkok, ThailandOverall official - principal investigator
- Yale UniversityReponsible party - principal investigator
- United States ArmyStudy chair
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- South East Asia Research Collaboration with HawaiiCollaborator
- University of California, San FranciscoCollaborator
- University of HawaiiCollaborator
- National Institute of Mental Health (NIMH)Collaborator
- United States ArmyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.